Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134635 | 0.85 | SMN1; SMN2 (0.44) | NNMTPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6134928 | 0.85 | NNMT (0.42) | NNMTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6133377 | 0.83 | NPC1 (0.44) | NNMTRAB9ANPC1CES2CES1 | |
| SCHEMBL6133524 | 0.81 | NNMT (0.41) | NNMTRAB9ANPC1CYP1A2CES2 | |
| SCHEMBL6135277 | 0.78 | CES2 (0.41) | NNMTRAB9ANPC1CES2CES1 | |
| SCHEMBL6134151 | 0.78 | NNMT (0.45) | NNMTRAB9ANPC1CES1POLB | |
| SCHEMBL6134224 | 0.76 | HTT (0.52) | RAB9ANPC1POLBKMT2AMEN1 | |
| SCHEMBL6134053 | 0.75 | CES2 (0.51) | RAB9ANPC1CES2CES1POLB | |
| SCHEMBL6134193 | 0.75 | CTNNB1 (0.50) | NNMTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6133746 | 0.75 | NPC1 (0.44) | NNMTRAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | NNMT 2041/4885RAB9A 1824/4885NPC1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.